An international clinical trial has revealed that tirzepatide, a medication commonly used for weight loss and diabetes management, could also help people with a specific type of heart failure linked to obesity.
The trial followed 731 patients with diastolic heart failure and obesity over two years, uncovering significant benefits beyond weight loss.
Dr. Christopher Kramer, chief of cardiovascular medicine at UVA Health, emphasized the drug’s potential. “This class of drug continues to show benefits far beyond weight loss,” he said. “It could become a key treatment for patients with obesity-related heart failure and preserved heart function.”
Understanding Diastolic Heart Failure
In nearly half of heart failure cases, the heart’s left ventricle becomes stiff, making it difficult to pump blood efficiently.
This condition, called diastolic heart failure or heart failure with preserved ejection fraction, is often linked to obesity. Excess weight increases the strain on the heart, leading to problems over time.
Given this connection, researchers wondered if tirzepatide, marketed as Zepbound, might help.
The drug belongs to a class of medications that not only promote weight loss but also have effects on other health issues, including diabetes. The trial results suggest that its benefits extend to heart health.
Key Findings from the Trial
The study, presented at an American Heart Association meeting in Chicago and published in leading journals like The New England Journal of Medicine, showed encouraging results.
Patients taking tirzepatide experienced improvements in their heart failure symptoms and overall health.
Key benefits included:
- Improved physical ability: Patients who took tirzepatide could walk farther in six minutes compared to those on a placebo.
- Reduced inflammation: The drug significantly lowered levels of a biological marker linked to inflammation and heart disease risk.
- Fewer worsening cases: Over the two years, only 36 participants on tirzepatide saw their heart failure worsen or died, compared to 56 in the placebo group.
- Weight loss: On average, participants on tirzepatide lost 11.6% of their body weight.
- Improved heart structure: MRIs showed that tirzepatide reduced the heart’s weight and the amount of fat around it, reversing some of the damage caused by obesity.
The side effects were generally mild, with nausea and diarrhea being the most common issues.
A New Tool for Heart Health
Dr. Kramer also led a related study analyzing how tirzepatide affected the heart’s structure and function. The findings revealed that the drug helped reverse some of the heart changes caused by obesity.
“This drug is reversing the abnormal properties of the heart brought on by obesity,” Kramer explained. “There is much more to these drugs than weight loss alone.”
As obesity rates continue to rise globally, conditions like diastolic heart failure are becoming more common. The results of this study offer hope for a new treatment option that targets both the root cause—obesity—and its impact on the heart.
Looking Ahead
While more research is needed to confirm these findings and explore long-term effects, the study suggests that tirzepatide could be a game-changer for patients with obesity-related heart failure.
By addressing both weight and heart health, the drug provides a holistic approach to managing a challenging condition.
For patients and healthcare providers, this breakthrough offers a promising new way to improve quality of life and potentially extend survival in those affected by obesity and heart failure.
If you care about heart disease, please read studies about a big cause of heart failure, and common blood test could advance heart failure treatment.
For more information about heart health, please see recent studies about a new way to repair human heart, and results showing drinking coffee may help reduce heart failure risk.
Copyright © 2024 Knowridge Science Report. All rights reserved.
